GenMark Diagnostics (GNMK) Tops Q1 EPS by 1c

GenMark Diagnostics (NASDAQ: GNMK) reported Q1 EPS of ($0.21), $0.01 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $17.25 million.

GenMark is reconfirming prior 2018 revenue guidance of $68 to $72 million. Gross margin is expected to be in the 30% range. The Company continues to expect ePlex placements of 140-170 net new analyzers, and an annuity per ePlex placement in the $100,000 to $120,000 range.

For earnings history and earnings-related data on GenMark Diagnostics (GNMK) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• SanDisk upgraded at JPMorgan after investor day; shares climb